Investment banks updating ilmn stock price forecast advise cautious optimism. The biotech capital markets show resilience, and Illumina’s healthy balance sheet with over $1.5B in cash reserves provides flexibility for R&D scaling in 2024– Our review of ILMN's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts. Be the first to see our newest insights and key updates across all datasets Macro headwinds like inflation and interest rates factor into the ilmn stock price forecast, but sector-specific catalysts — such as reduced supply chain bottlenecks — could counterbalance downside risks.